Background: The objective of this retrospective study was to determine, within one institution, local relapse rate and survival for women with early-stage breast cancer treated with breast-conserving surgery followed by radiotherapy.
Material And Methods: All women with infiltrating early-stage breast cancer who underwent post-operative whole breast irradiation at our institution in the period 14.06.99-8.03.2002 were included in the study. A CT-based 3D dose calculation was performed in all patients.
Results: 222 women received 50 Gy whole-breast irradiation after breast-conserving surgery in the study period. 51 patients received adjuvant systemic therapy according to national guidelines. Median age at diagnosis was 59 years (34-82 years). Median tumour size was 12 mm (1-30 mm) and 86.5 % of the patients were N0. During a follow-up (median) of 96 months (28-111 months), local recurrence was observed in three of 222 patients (1.4 %; 95 % CI [0.5-4.4 %]) in the ipsilateral breast. The estimated 8-year breast-cancer specific survival was 95 % and total survival was 90 %.
Interpretation: Our data demonstrate excellent local disease control in women with low-risk early-stage breast cancer (about 25 % were on adjuvant systemic therapy) who undergo breast-conserving surgery and 50 Gy whole-breast irradiation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4045/tidsskr.09.0484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
J Clin Endocrinol Metab
January 2025
Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Context: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR+EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
View Article and Find Full Text PDFXenogeneic platelet-rich plasma lotion for preventing acute radiation dermatitis in patients with breast cancer undergoing radiotherapy: An open-label, randomized controlled trial.
JPRAS Open
March 2025
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.
Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.
Introduction: Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast carcinomas. In the last two decades, both nipple-sparing mastectomy (NSM) and skin-sparing mastectomy (SSM) with immediate reconstruction have been used in the surgical management. The aim of our study was to analyze the outcomes of the combined treatment of patients with TNBC treated with NSM or SSM.
View Article and Find Full Text PDFThe Association of Care Fragmentation on Overall Survival for Early Stage Breast Cancer.
J Surg Res
January 2025
Department of Surgery, Duke University Medical Center, Durham, North Carolina; Duke Cancer Institute, Durham, North Carolina. Electronic address:
Introduction: Optimal treatment of stage I-III breast cancer requires multimodal therapies. Patients can receive these therapies at one or multiple facilities. Herein, we evaluated the association of receiving treatment at more than one facility and distance to that facility on overall survival.
View Article and Find Full Text PDFEstimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS.
EBioMedicine
January 2025
MGH Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:
Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Methods: In UKCTOCS between Apr-2001 and Sep-2005, 101,314 postmenopausal women were randomised to no screening (NS) and 50,625 to annual multimodal screening (MMS) (until Dec-2011) using serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!